Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ: VCYT )

41.56 -1.94 (-4.46%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,128,481
Open 43.35
Bid (Size) 41.05 (1)
Ask (Size) 42.00 (1)
Prev. Close 43.50
Today's Range 40.46 - 43.50
52wk Range 18.61 - 47.32
Shares Outstanding 67,473,870
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why VERACYTE INC (NASDAQ:VCYT) qualifies as a high growth stock.
A fundamental and technical analysis of (NASDAQ:VCYT): Is VERACYTE INC (NASDAQ:VCYT) suited for high growth investing? 
Via Chartmill
New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
From Veracyte, Inc.
Via Business Wire

Performance

YTD
+2.77%
+2.77%
1 Month
-5.07%
-5.07%
3 Month
+13.93%
+13.93%
6 Month
+41.99%
+41.99%
1 Year
+66.24%
+66.24%

More News

Read More
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
From Veracyte, Inc.
Via Business Wire
Demystifying Veracyte: Insights From 7 Analyst Reviews
Via Benzinga
Exploring NASDAQ:VCYT's high growth characteristics.
Via Chartmill
Should you consider VERACYTE INC (NASDAQ:VCYT) for high growth investing?
Via Chartmill
Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
From Veracyte, Inc.
Via Business Wire
Navigating 9 Analyst Ratings For Veracyte
Via Benzinga
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is NASDAQ:VCYT a Fit for high Growth Investing Strategies?
Via Chartmill
Breaking Down Veracyte: 4 Analysts Share Their Views
Via Benzinga
Smaller Cap Biotechs Are In Season: How Are We Doing?
Via Talk Markets
Veracyte Announces Third Quarter 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
From Veracyte, Inc.
Via Business Wire
New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men
From Veracyte, Inc.
Via Business Wire
Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
From Veracyte, Inc.
Via Business Wire
Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
From Veracyte, Inc.
Via Business Wire
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81
Via Investor's Business Daily
Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Via Benzinga
Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.